Breaking News
FDA Clears New World Medical's VIA360 Surgical System for Ophthalmic Procedures

New World Medical has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for...

read more
FDA Clears New World Medical's VIA360 Surgical System for Ophthalmic Procedures
February 19, 2025
FDA Accepts Biologics License Application for AVT06, Alvotech’s Biosimilar to Eylea

Alvotech and Teva Pharmaceuticals have announced that the U.S. Food and Drug Administration (FDA) ha...

read more
FDA Accepts Biologics License Application for AVT06, Alvotech’s Biosimilar to Eylea
February 19, 2025
FDA Approves Amended Label for Izervay in the Treatment of Geographic Atrophy

The FDA has approved an amended label for avacincaptad pegol intravitreal solution (Izervay; Astella...

read more
FDA Approves Amended Label for Izervay in the Treatment of Geographic Atrophy
February 14, 2025
FDA Approves Continuous Delivery Ranibizumab Injection (Susvimo) for Diabetic Macular Edema

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection 100 mg/mL (Susvimo; G...

read more
FDA Approves Continuous Delivery Ranibizumab Injection (Susvimo) for Diabetic Macular Edema
February 05, 2025
FDA Approves Zeiss MEL 90 Excimer Laser for Refractive Surgery

The FDA has officially approved the Zeiss MEL 90 excimer laser for all three major indications: myop...

read more
FDA Approves Zeiss MEL 90 Excimer Laser for Refractive Surgery
January 14, 2025
FDA Accepts Revised Supplemental New Drug Application for IZERVAY

The U.S. Food and Drug Administration (FDA) has accepted a revised supplemental New Drug Application...

read more
FDA Accepts Revised Supplemental New Drug Application for IZERVAY
January 13, 2025
Alcon Recalls Systane Ultra PF Lot Over Potential Fungal Contamination

Alcon Laboratories has announced a voluntary recall of Lot 10101 of Systane Lubricant Eye Drops Ultr...

read more
Alcon Recalls Systane Ultra PF Lot Over Potential Fungal Contamination
December 30, 2024
FDA Clears SB-007 Gene Therapy IND for Stargardt Disease

The FDA has cleared an Investigational New Drug (IND) application for SB-007, an adeno-associated vi...

read more
FDA Clears SB-007 Gene Therapy IND for Stargardt Disease
December 13, 2024
Bausch + Lomb Acquires ELIOS System, Expanding Glaucoma Treatment Options

Bausch + Lomb Corp. has announced the acquisition of Elios Vision Inc., the developer of the ELIOS p...

read more
Bausch + Lomb Acquires ELIOS System, Expanding Glaucoma Treatment Options
December 12, 2024
Adverse Effects Identified Following Faricimab Treatment for Eye Conditions

Researchers from the University Hospital Zurich have reported cases of sterile intraocular inflammat...

read more
Adverse Effects Identified Following Faricimab Treatment for Eye Conditions
October 15, 2024
More